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Drug delivery systems are defined as formulations aiming for transportation of a drug to the desired area of action within the body.
The basic component of drug delivery systems is an appropriate carrier that protects the drug from rapid degradation or clearance
and thereby enhances drug concentration in target tissues. Based on their biodegradable, biocompatible, and nonimmunogenic
structure, niosomes are promising drug carriers that are formed by self-association of nonionic surfactants and cholesterol in
an aqueous phase. In recent years, numerous research articles have been published in scientific journals reporting the potential
of niosomes to serve as a carrier for the delivery of different types of drugs. The present review describes preparation methods,
characterization techniques, and recent studies on niosomal drug delivery systems and also gives up to date information regarding
recent applications of niosomes in drug delivery.
1. Introduction
Delivering drug with a controlled rate and targeted delivery
received much attention in recent years. The application of
nanotechnology to medicine has provided the development
of multifunctional nanoparticles that, acting as drug carriers,
can be loaded with different drugs. Nanocarriers present
a great approach in drug delivery with promising features
such as protection of drug from degradation and cleavage,
controlled release, and in case of targeted delivery approaches
the delivery of drug molecules to the target sites [1].
Niosomes are one of the promising drug carriers that
have a bilayer structure and are formed by self-association
of nonionic surfactants and cholesterol in an aqueous phase.
Niosomes are biodegradable, biocompatible, and nonim-
munogenic. They have long shelf life, exhibit high stability,
and enable the delivery of drug at target site in a controlled
and/or sustained manner [2]. In recent years, the potential of
niosomes as a drug carrier has been extensively studied [3–
5]. Various types of nonionic surfactants have been reported
to form niosomes and enable the entrapment of a large
number of drugs with a wide range of solubility [6–8]. The
composition, size, number of lamellae, and surface charge
of niosomes can be varied and optimized to enhance the
performance of niosomes for drug delivery.
The aim of this review is to present the fundamentals
of niosome preparation and characterization as well as a
description of their use in drug delivery, with particular
attention to more recent studies. This review will provide an
overview on the increasing interest on niosomes in the field
of drug delivery.
2. Structure and Components of Niosomes
Themain components of niosomes are nonionic surfactants,
hydration medium and lipids such as cholesterol. The list
of materials used in the preparation of niosomes has been
shown in Table 1.The self-assembly of nonionic surfactants in
aqueous media results in closed bilayer structures (Figure 1).
A high interfacial tension betweenwater and the hydrophobic
tails of the amphiphile causes them to associate.The steric and
hydrophilic repulsion between the head groups of nonionic
surfactant ensure that hydrophilic termini point outwards
and are in contact with water. The assembly into closed
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Table 1: The materials used in niosome preparation.
Nonionic surfactants Examples References
Alkyl ethers
(i) Alkyl glycerol ethers Hexadecyl diglycerol ether (C16G2) [9]
(ii) Polyoxyethylene glycol alkyl ethers (Brij) Brij 30, Brij 52, Brij 72, Brij 76, Brij 78 [10–12]
Crown ethers Bola [13, 14]
Alkyl esters
(i) Sorbitan fatty acid esters (Spans) Span 20, Span 40, Span 60, Span 80, Span 65,Span 85 [15–18]
(ii) Polyoxyethylene sorbitan fatty acid esters (Tweens) Tween 20, Tween 40, Tween 60, Tween 80,Tween 65, Tween 85 [7, 19, 20]
Alkyl amides
(i) Glycosides C-Glycoside derivative surfactant (BRM-BG) [21]
(ii) Alkyl polyglucosides Octyl-decyl polyglucoside (OrCG110), decylpolyglucoside (OrNS10) [22]
Fatty alcohols or fatty acids
(i) Fatty alcohols Stearyl alcohol, cetyl alcohol, myristyl alcohol [23]
(ii) Fatty acids Stearic acid, palmitic acid, myristic acid [23]
Block copolymer
(i) Pluronic Pluronic L64, Pluronic 105 [24, 25]
Lipidic components
Cholesterol [26]
l-𝛼-Soya phosphatidyl choline [27]
Charged molecule
Negative charge Diacetyl phosphate, phosphatidic acid,lipoamino acid, dihexadecyl phosphate [28, 29]
Positive charge Stearylamine, stearyl pyridinium chloride,cetyl pyridinium chloride [29]
Bilayer
Hydrophilic head
Aqueous core
Hydrophobic tail
Figure 1: Structure of niosomes.
bilayers usually requires some input of energy such as
mechanical or heat. Niosomes can be categorized in three
groups according to their sizes and bilayers. Small unilamellar
vesicles (SUV) (10–100 nm), large unilamellar vesicles (LUV)
(100–3000 nm), and multilamellar vesicles (MLV) where
more than one bilayer is present.
2.1. Nonionic Surfactants. Nonionic surfactants are a class
of surfactants, which have no charged groups in their
hydrophilic heads. They are more stable and biocompatible
and less toxic compared to their anionic, amphoteric, or
cationic counterparts [41]. Therefore they are preferred for
formation of stable niosome for in vitro and in vivo appli-
cations. Nonionic surfactants are amphiphilic molecules that
comprise two different regions: one of them is hydrophilic
(water-soluble) and the other one is hydrophobic (organic-
soluble). Alkyl ethers, alkyl esters, alkyl amides, fatty acids
are the main nonionic surfactant classes used for niosome
production. The hydrophilic-lipophilic balance (HLB) and
critical packing parameter (CPP) values play a critical role
in the selection of surfactant molecules for niosome prepa-
ration.
2.1.1. Hydrophilic-Lipophilic Balance (HLB). HLB is a dimen-
sionless parameter, which is the indication of the solubility of
the surfactant molecule.TheHLB value describes the balance
between the hydrophilic portion to the lipophilic portion of
the nonionic surfactant. The HLB range is from 0 to 20 for
nonionic surfactants.The lowerHLB refers tomore lipophilic
surfactant and the higher HLB to more hydrophilic surfac-
tant. Surfactants with a HLB between 4 and 8 can be used
for preparation of vesicle [42]. Hydrophilic surfactants with
a HLB value ranging from 14 to 17 are not suitable to form a
bilayer membrane due to their high aqueous solubility [43].
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Howeverwith the addition of an optimum level of cholesterol,
niosomes are indeed formed from polysorbate 80 (HLB
value = 15) and Tween 20 (HLB value = 16.7) [44, 45].
Tween 20 forms stable niosome in the presence of equimolar
cholesterol concentration. The interaction occurs between
the hydrophobic part of the amphiphile next to head group
and the 3-OH group of cholesterol at an equimolar ratio
and this interaction could explain the effect of cholesterol on
the formation and hydration behavior of Tween 20 niosomal
membranes [46, 47].
Drug entrapment efficiency of the niosomes is also
affected by HLB value of surfactant [48]. Shahiwala et al.
have incorporated nimesulide into niosomes using lipid film
hydration technique by changing the HLB. They found that
as the HLB value of surfactant decreases from 8.6 to 1.7,
entrapment efficiency decreases [43, 49].
2.1.2. Critical Packing Parameter (CPP). During the niosomal
preparation, the geometry of the vesicle depends upon the
critical packing parameter. On the basis of the CPP of a sur-
factant, the shape of nanostructures formed by self-assembly
of amphiphilic molecules can be predicted. Critical packing
parameter depends on the symmetry of the surfactant and
can be defined using following equation [50, 51]:
CPP = V
𝑙
𝑐
× 𝑎
0
, (1)
where V is hydrophobic group volume, 𝑙
𝑐
is the critical
hydrophobic group length, and 𝑎
0
is the area of hydrophilic
head group. If CPP ≤ 1/3 corresponding, for example, to a
bulky head group, small hydrophobic tail spherical micelles
may form. Nonspherical micelles may form if 1/3 ≤ CPP ≤
1/2, and bilayer vesicles can occur if 1/2 ≤ CPP ≤ 1. Inverted
micelles form if CPP ≥ 1 when the surfactant is composed
of a voluminous tail and a small hydrophobic tail [47]. CPP
could be considered as a tool for realizing, rationalizing, and
predicting the self-assembled structure and itsmorphological
transition in amphiphilic solutions [52].
2.2. Cholesterol. In the bilayer structure of niosomes, choles-
terol forms hydrogen bonds with hydrophilic head of a
surfactant [19, 53]. Cholesterol content of niosomes thereby
influences the structures of niosomes and physical properties
such as entrapment efficiency, long time stability, release of
payload, and biostability [17, 46]. Cholesterol improves the
rigidity of vesicles and stabilizes niosomes towards desta-
bilizing effects induced by plasma and serum components
and decreases the permeability of vesicles for entrapped
molecules thus inhibiting leakage [54].
Drug entrapment efficiency plays an important role in
niosomal formulations and it can be altered by varying
the content of cholesterol. Agarwal et al. demonstrated that
cholesterol improves the stability of enoxacin loaded niosome
with increasing cholesterol content, resulting in increases
of entrapment efficiency [55]. The effect of cholesterol on
flurbiprofen entrapment was studied by Mokhtar et al. and
cholesterol was found to have little effect on the flurbiprofen
entrapment into Span 20 and Span 80 niosomes. However,
a significant increase in entrapment efficiency of flurbiprofen
was obtained when 10% of cholesterol was incorporated into
niosomes prepared from Span 40 and Span 60 followed
by a decrease in encapsulation efficiency of the drug upon
further increase in cholesterol content [56]. According to the
reported results, the addition of cholesterol and its amounts
needs to be optimized depending on the physical-chemical
characteristic of surfactants and loaded drugs.
2.3. Charged Molecule. Charged molecules increase the sta-
bility of the vesicles by the addition of charged groups to
the bilayer of vesicles. They increase surface charge density
and thereby prevent vesicles aggregation. Dicetyl phosphate
and phosphatidic acid are most used negatively charged
molecules for niosome preparation and, similarly, steary-
lamine and stearyl pyridinium chloride are well-known posi-
tively chargedmolecules used in niosomal preparations. Nor-
mally, the chargedmolecule is added in niosomal formulation
in an amount of 2.5–5mol%. However increasing the amount
of charged molecules can inhibit niosome formation [29].
3. Methods of Preparation
3.1.Thin-FilmHydrationMethod (TFH). Thin-filmhydration
method is a simple and well-known preparation method. In
this method, the surfactants, cholesterol, and some additives
such as chargedmolecules are dissolved in an organic solvent
in a round bottomed flask. Then the organic solvent is
removedusing a rotary vacuumevaporator to obtain thin film
on the inside wall of the flask. An aqueous solution of drug
is added and the dry film is hydrated above the transition
temperature (𝑇
𝑐
) of the surfactant for specified time with
constant shaking [57, 58].Multilamellar niosomes are formed
by this method.
3.2. Ether InjectionMethod (EIM). In ether injectionmethod,
the surfactants with additives are dissolved in diethyl ether
and injected slowly through a needle in an aqueous drug
solution maintained at a constant temperature, which is
above the boiling point of the organic solvent. The organic
solvent is evaporated using a rotary evaporator. During the
vaporization the formation of single layered vesicles occurs
[59–61].
3.3. Reverse Phase Evaporation Method (REV). In this
method, niosomal ingredients are dissolved in a mixture of
ether and chloroform and added to aqueous phase containing
the drug. The resulting mixture is sonicated in order to
form an emulsion and the organic phase is evaporated. Large
unilamellar vesicles are formed during the evaporation of the
organic solvent [62–64].
3.4.MicrofluidizationMethod. Themicrofluidizationmethod
is based on submerged jet principle. In this method, the
drug and the surfactant fluidized streams interact at ultrahigh
velocities, in precisely defined micro channels within the
interaction chamber. The high speed impingement and the
energy involved leads to formation of niosomes.Thismethod
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offers greater uniformity, smaller size, unilamellar vesicles,
and high reproducibility in the formulation of niosomes [65,
66].
3.5. Supercritical Carbon Dioxide Fluid (scCO
2
). Manosroi et
al. have described the supercritical reverse phase evaporation
technique for niosome formation [67, 68].They added Tween
61, cholesterol, glucose, PBS, and ethanol into the view cell
and the CO
2
gas was introduced into the view cell. After
magnetic stirring until equilibrium, the pressure was released
and niosomal dispersions were obtained [67]. This method
enables one step production and easy scale-up.
3.6. Proniosome. Proniosome technique includes the coating
of a water-soluble carrier such as sorbitol and mannitol with
surfactant. The coating process results in the formation of a
dry formulation. This preparation is termed “Proniosomes”
which requires to be hydrated before being used. The nio-
somes are formed by the addition of the aqueous phase. This
method helps in reducing physical stability problems such as
the aggregation, leaking, and fusion problem and provides
convenience in dosing, distribution, transportation, and
storage showing improved results compared to conventional
niosomes [69].
3.7. Transmembrane pH Gradient. In this method, surfactant
and cholesterol are dissolved in chloroform and evaporated to
form a thin lipid film on the wall of a round bottomed flask.
The film is hydrated with a solution of citric acid (pH = 4) by
vortex mixing and the resulting product is freeze-thawed for
niosome formation.The aqueous solution of drug is added to
this niosomal suspension, after that phosphate buffer is added
to maintain pH between 7.0 and 7.2 [70]. According to this
method, the interior of niosome has a more acidic pH value
than the outer medium. The added unionized drug passes
through the niosomemembrane and enters into the niosome.
Thedrug ionizes in an acidicmediumand cannot escape from
the niosomal bilayer [71].
3.8. Heating Method. This is a patented method which was
created byMozafari et al. [72, 73]. Surfactants and cholesterol
are separately hydrated in buffer and the solution is heated to
120∘Cwith stirring to dissolve cholesterol.The temperature is
reduced and surfactants and other additives are then added
to the buffer in which cholesterol is dissolved while stirring
continues. Niosomes form at this stage, are left at room
temperature, and then are kept at 4-5∘C under nitrogen
atmosphere until use [53].
3.9. The “Bubble” Method. In this method, surfactants, addi-
tives, and the buffer are added into a glass flask with
three necks. Niosome components are dispersed at 70∘C
and the dispersion is mixed with homogenizer. After that,
immediately the flask is placed in a water bath followed by
the bubbling of nitrogen gas at 70∘C. Nitrogen gas is passed
through a sample of homogenized surfactants resulting in
formation of large unilamellar vesicles [74].
4. Characterization of Niosomes
The characterization of niosome is essential for the clini-
cal applications. Characterization parameters have a direct
impact on the stability of niosomes and a significant effect on
their in vivo performance. Therefore these parameters such
as morphology, size, polydispersity index (PI), number of
lamellae, zeta potential, encapsulation efficiency, and stability
must be evaluated.
4.1. Size and Morphology. Dynamic light scattering (DLS)
[75], scanning electronmicroscopy (SEM) [76], transmission
electron microscopy (TEM) [77], freeze fracture replication-
electron microscopy (FF-TEM) [68], and cryotransmission
electron microscopy (cryo-TEM) [67] are the most used
methods for the determination of niosome sizes andmor-
phology. DLS provides simultaneously cumulative infor-
mation of particle size and valuable information on the
homogeneity of the solution. A single sharp peak in the DLS
profile implies existence of a single population of scatterers.
The PI is helpful in this respect. It less than 0.3 corresponds
to a homogenous population for colloidal systems [75]. The
microscopic approaches are generally used to characterize the
morphology of the niosomes.
4.2. Zeta Potential. Surface zeta potential of niosomes can be
determined using zetasizer andDLS instruments.The surface
charge of niosome plays an important role in the behavior
of niosomes. In general, charged niosomes are more stable
against aggregation than uncharged vesicles. Bayindir and
Yuksel prepared paclitaxel loaded niosomes and investigated
the physicochemical properties such as zeta potential of
niosomes. They found that negative zeta potential values
ranging between −41.7 and −58.4mV are sufficiently high for
electrostatic stabilization of niosomes [12].
4.3. Bilayer Characterization. Bilayer characteristics of nio-
somes have an importance on drug entrapment efficiency.
The number of lamellae can be determined by AFM, NMR,
and small angle X-ray scattering (SAXS) for multilamellar
vesicles [54]. Membrane rigidity of niosomal formulations
can be measured by means of the mobility of fluorescence
probe as a function of temperature [20]. DPH (1,6 diphenyl-
1,3,5-hexatriene) is most used fluorescent probe and added
to niosomal dispersion. DPH normally exists in hydrophobic
region in the bilayer membrane. The microviscosity of nio-
somal membrane is determined by fluorescence polarization.
High fluorescence polarization means high microviscosity of
the membrane [78]. Moreover, the bilayer thickness can be
characterized using the latter method, together with the in
situ energy-dispersive X-ray diffraction (EDXD) [79].
4.4. Entrapment Efficiency. Entrapment efficiency (EE%) is
defined as the portion of the applied drug which is entrapped
by the niosomes. Unencapsulated free drug can be removed
from the niosomal solution using centrifugation [80], dialysis
[24], or gel chromatography [81]. After this step the loaded
drug can be released from niosomes by destruction of
Journal of Nanomaterials 5
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Figure 2: Niosomes in drug delivery.
vesicles. Niosomes can be destroyed with the addition of
0.1% Triton X-100 or methanol to niosomal suspension. The
loaded and free drug concentration can be determined by a
spectrophotometer [82] or high-performance liquid chroma-
tography (HPLC) [83].
4.5. Stability. The stability of niosomes can be evaluated
by determining mean vesicle size, size distribution, and
entrapment efficiency over several month storage periods
at different temperatures. During storage the niosomes are
sampled at regular intervals of time and the percentage of
drug which is retained into the niosomes is analyzed by UV
spectroscopy or HPLC methods [82, 84].
4.6. In Vitro Release. One often applied method to study in
vitro release is based on using of dialysis tubing. A dialysis
bag is washed and soaked in distilled water. After 30mins,
the drug loaded niosomal suspension is transferred, into this
bag. The bag containing the vesicles is immersed in buffer
solution with constant shaking at 25∘C or 37∘C. At specific
time intervals, samples were removed from the outer buffer
(releasemedium) and replaced with the same volume of fresh
buffer. The samples are analyzed for the drug content by an
appropriate assay method [17].
5. Niosomes as Drug Carriers
Niosomes are very promising carriers for the delivery of
numerous pharmacological and diagnostic agents. A number
of publications have reported the preparation, characteri-
zation, and use of niosomes as drug carriers. Because of
their nonionic nature, they offer excellent biocompatibility
and low toxicity. The unique structure of niosomes allows
the development of effective novel drug delivery systems
with ability of loading both hydrophilic and lipophilic drugs.
Hydrophilic drugs and lipophilic drugs are entrapped into the
aqueous core and membrane bilayer of niosome respectively
(Figure 2).
5.1. Anticancer Drug Delivery. The current treatment for
cancer is usually chemotherapy. The therapeutic efficacy of
many anticancer drugs is limited by their poor penetration
into tumor tissue and by their severe side effects on healthy
cells. Various attempts have been made to overcome these
drawbacks, including the use of niosomes as a novel drug
delivery system.
5.1.1. Melanoma. Artemisone is a 10-amino-artemisinin
derivative exhibiting antimalarial activity and also possessing
antitumor activity. Dwivedi et al. encapsulated artemisone
in niosomes using thin-film hydration method. The for-
mulations showed highly selective cytotoxicity towards the
melanoma cells with negligible toxicity towards the normal
skin cells [85]. 5-Fluorouracil (5-FU), largely used in the
treatment of different forms of skin cancers, was encapsulated
in an innovative bola-niosomal system made up of 𝛼,𝜔-hex-
adecyl-bis-(1-aza-18-crown-6) (bola-surfactant), Span 80, and
cholesterol. The percutaneous permeation of 5-FU-loaded
bola-niosomes was evaluated by using human stratum
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corneum and epidermis membranes. Bola-niosomes pro-
vided an increase of the drug penetration of 8- and 4-fold
with respect to free drug aqueous solution [13]. The use
of cisplatin is limited due to its severe toxic effects. Gude
et al. synthesized niosomal cisplatin by using Span 60 and
cholesterol and investigated the antimetastatic activity in
experimental metastatic model of B16F10 melanoma. Their
results suggest that cisplatin encapsulated in niosomes has
significant antimetastatic activity and reduced toxicity when
compared to free cisplatin [86].
5.1.2. Breast Cancer. 5-FU-loadedpolyethylene glycol- (PEG-)
coated and uncoated bola-niosomes were prepared by Cosco
et al. and were tested on breast cancer cell lines (MCF-
7 and T47D). Both bola-niosome formulations provided
an increase in the cytotoxic effect with respect to the free
drug. In vivo experiments on MCF-7 xenograft tumor SCID
mice models showed a more effective antitumor activity of
the PEGylated niosomal 5-FU at a concentration ten times
lower (8mg/kg) than that of the free solution of the drug
(80mg/kg) after a treatment of 30 days [87]. Cantharidin-
entrapped niosomes were prepared by injection method.
Their potential in enhancing the antitumor activities of the
drug and reducing its toxicity was evaluated on human
breast cancer cell line MCF-7. Moreover, in vivo therapeutic
efficacy was investigated in S
180
tumor-bearing mice. Mice
treatedwith 1.0mg/kg niosomal cantharidin showed themost
effective antitumor activity, with an inhibition rate of 52.76%,
which was significantly higher than that of the same concen-
tration of free cantharidin (1.0mg/kg, 31.05%) [88]. Recently,
tamoxifen citrate niosomes were prepared by film hydration
technique for localized cancer therapy through in vitro
breast cancer cytotoxicity as well as in vivo solid antitumor
efficacy. The optimized niosomal formulation of tamoxifen
showed significantly enhanced cellular uptake (2.8-fold) and
exhibited significantly greater cytotoxic activity on MCF-7
breast cancer cell line. In vivo experiments showed enhanced
tumor volume reduction induced by niosomal tamoxifen
when compared to free tamoxifen [89].
5.1.3. Ovarian Cancer. Uchegbu et al. prepared doxorubicin
loaded niosomes. The activity of doxorubicin in hexadecyl
diglycerol ether (C
16
G
2
) and Span 60 niosomes was studied
against a human ovarian cancer cell line and its doxorubicin
resistant subline. According to the results, there was a slight
reduction in the IC
50
against the resistant cell line when the
drug was encapsulated in Span 60 niosomes in comparison
to the free drug in solution [90].
5.1.4. Lung Cancer. Adriamycin was encapsulated into the
noisome using a monoalkyl triglycerol ether by Kerr et al.
and the activity of niosomal adriamycin compared with free
adriamycin solution on human lung tumor cells grown in
monolayer and spheroid culture and in tumor xenografted
nude mice. The growth delay (i.e., the time taken for
the tumor volume to double) was significantly longer for
adriamycin (15 days) and niosomal adriamycin (11 days)
than for control (5.8 days). It is possible that the thera-
peutic ratio of adriamycin could be further enhanced by
administration in niosomal form [91]. In another study,
pentoxifylline loaded niosomes were prepared by lipid film
hydration method. Intravenous administration of niosomal
pentoxifylline (6mg/kg and 10mg/kg) resulted in significant
reduction in lung nodules in an experimental metastatic
B16F10 model suggesting accumulation of pentoxifylline in
a distant target. Light microscopic observation of histologic
sections showed a decrease in number of tumor islands in the
lung [92].
5.2. Targeted Delivery. The efficiency and particularly the
specificity of cellular targeting of niosomal drug delivery
systems can be further improved by active targeting for
tumor therapy, by using a ligand coupled to the surface of
niosomes, which could be actively taken up, for example,
via a receptor-mediated endocytosis. Niosome surfaces can
be conjugated with small molecules and/or macromolecu-
lar targeting ligands to enable cell specific targeting [93].
Proteins and peptides, carbohydrates, aptamers, antibod-
ies, and antibody fragments are the most commonly used
molecules that bind specifically to an overexpressed tar-
get on the cell surface [94–96]. Bragagni et al. developed
brain targeted niosomal formulation using with the glucose-
derivative as a targeting ligand. They formulated nioso-
mal doxorubicin composed of span : cholesterol : solulan : N-
palmitoylglucosamine. Preliminary in vivo studies in rats
showed that intravenous administration of a single dose of
the developed targeted-niosomal formulation with respect
to the commercial one was able to significantly reduce the
hearth accumulation of the drug and to keep it longer
in the blood circulation and also to allow the achieve-
ment of well detectable doxorubicin brain concentrations
[30]. Moreover, an efficient tumor-targeted niosomal deliv-
ery system was designed by Tavano et al. Niosomes were
prepared from a mixture of Pluronic L64 surfactant and
cholesterol and doxorubicin was entrapped into the niosome.
After the preparation, transferrin was conjugated to nio-
somes surface using EDC (N-[3-(dimethylamino)propyl]-N-
ethylcarbodiimide hydrochloride) chemistry. Doxorubicin-
loaded niosome anticancer activity was achieved against
MCF-7 and MDA-MB-231 tumor cell lines, and a significant
reduction in viability in a dose and time related manner was
observed [24].The information about some recent studies on
niosomal targeted drug delivery is summarized in Table 2.
5.3. Codrug Delivery. In recent years, nanoparticles have
emerged as a promising class of carriers in codelivery of
multiple drugs for combination therapy [97]. Combinational
therapies enhance therapeutic efficacy and decrease dosage
while obtaining equal or greater levels of efficacy and
reducing drug resistance [98]. Anticancer drugs often have
serious side effects. With multidrug delivery system Pasut et
al. achieved higher anticancer activity for carcinoma cells,
whereas multidrug delivery system decreased cytotoxicity
against endothelial cells and cardiomyocytes, with respect to
free drug treatment. In their system, they have developed
simultaneous anticancer drug epirubicin and nitric oxide car-
rying system, in which nitric oxide and epirubicin were cova-
lently conjugated to each terminal of PEG. Nitric oxide acts
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as not only protecting reagent against anthracycline induced
cardiomyopathy but also sensitizer of anticancer drug treat-
ment. In order to increase anticancer efficacy and enhance
cardiocyte protecting ability of codelivery system, they used
branched PEG as polymer backbone instead of linear one
[99]. Multidrug resistance (MDR) of malignant neoplasm
is the survival ability of cancer cells under the treatment
with structurally and functionally diverse anticancer drugs.
Increased drug efflux is mostly mediated by ATP-driven
extrusion pump proteins of the ATP-binding cassette (ABC)
superfamily, such as P-glycoprotein (P-gp) encoded byMDR-
1, multidrug resistance (MDR) proteins (MRPs/ABCC) and
breast cancer resistance protein (BCRP/ABCG2).These drug
efflux pumps noticeably decrease the intracellular concentra-
tion of numerous therapeutic agents [100]. Chemosensitizers,
such as Verapamil, Elacridar, Tariquidar, and cyclosporine A
mainly act as antagonist for P-gp and suppress drug efflux and
consequently recover chemosensitivity of MDR cancer cells.
Paclitaxel was coencapsulated with cyclosporine A within
actively targeted polymeric lipid-core micelles. P-gp inhibi-
tion with cyclosporine A caused an enhanced cytotoxicity of
paclitaxel. Micelles loaded with this dual cargo demonstrated
significantly higher cytotoxicity in the MDCKII-MDR1 cells
than micelles loaded with paclitaxel alone [101].
Niosomes are promising nanocarriers inmultidrug deliv-
ery applications [102]. Recently Sharma et al. reported the
dual encapsulation of hydrophobic curcumin andhydrophilic
doxorubicin in niosomes for cancer multidrug delivery [44].
Results showed that dual-drug loaded niosomes had higher
cytotoxicity on HeLa cells when compared to free drugs.
In another study, gallic acid, ascorbic acid, curcumin, and
quercetinwere encapsulated into the niosome as single agents
or in combination and the effect of the drugs coencapsulation
on the physicochemical properties of the carriers, on their
antioxidant properties and capability to release the encap-
sulated materials, was evaluated [103]. Furthermore, Mari-
anecci et al. prepared, characterized, and applied multidrug
niosomes using lidocaine and ibuprofen. Results suggest the
potential application of niosomes in dermal administration
of the two drugs at the same time in the same pharmaceutical
formulation, as useful carriers for the treatment of various
skin diseases, such as acute and chronic inflammations in
presence of pain [104].
5.4. Antibiotics. Niosomal carriers are also suitable for the
delivery of antibiotics and anti-inflammatory agents. These
carriers have been used extensively to improve poor skin
penetration and as well as enhance skin retention of the
drugs. Begum and coworkers designed rifampicin, a broad
spectrum antibiotic, encapsulated in a niosomal delivery
system.They investigated the activity of this system in in vitro
conditions and this study showed that niosomal formulation
of rifampicin is able to provide consistent and prolonged
release of the drug [105]. In another study to increase efficacy
of the antibiotics and reduce the dose, Akbari et al. syn-
thesized ciprofloxacin loaded niosomes using different non-
ionic surfactants and cholesterol in various concentrations
by film hydration method. Drug release through bilayers
and antibacterial activity of the niosomes were examined.
The results showed that cholesterol content and phase tran-
sition temperature of the surfactants influenced the perfor-
mance of niosomes. Besides, all formulations presentedmore
antibacterial activity as compared to free ciprofloxacin [106].
Vesicular systems, niosomes and liposomes, are mostly
used in ophthalmic controlled delivery. Abdelbary and El-
Gendy examined the feasibility of the niosomes as a car-
rier for the ophthalmic controlled delivery of gentamicin
antibiotic. Various surfactants (Tween 60, Tween 80, or Brij
35) were combined with cholesterol and a negative charge
inducer dicetyl phosphate in differentmolar ratios.The ability
of these vesicles to entrap the selected drug was evaluated
and the obtained results showed that entrapment efficiency
and the release rate of gentamicin is affected by cholesterol
content, type of surfactant, and the presence of charge
inducer. Gentamicin loaded niosomes composed of Tween
60, cholesterol, and dicetyl phosphate were the most effective
in terms of prolongation of in vitro drug release [107].
5.5. Anti-Inflammatory Drugs. Nonsteroidal anti-inflamma-
tory drugs (NSAIDs) loaded niosomes have been prepared
by several groups. These drugs may cause adverse effects
such as mucosal irritation. Topically applied NSAIDs loaded
niosomes can substantially improve drug permeation. To
investigate the potential application of the niosomes for deliv-
ery of anti-inflammatory agents,Marianecci et al. synthesized
ammonium glycyrrhizinate (AG) loaded niosomes using
several surfactants and cholesterol at various concentrations.
Drug entrapment efficiency, anisotropy, cytotoxicity and skin
tolerability, and some further analysis have been performed
for characterization.The AG-loaded niosomes demonstrated
no toxicity and good skin tolerability and were able to
improve the anti-inflammatory activity in mice. Moreover,
an enhancement of the anti-inflammatory activity of the
niosome delivered drug was observed on chemically induced
skin erythema in humans [7].
5.6. Antiviral Drugs. Niosomes have also demonstrated the
capability to deliver various antiviral agents. Ruckmani and
Sankar synthesized zidovudine, which is the first anti-HIV
compound approved for clinical use, encapsulated niosomes,
and examined their entrapment efficiency and as well as
sustainability of release. The niosomes were formulated by
combining the proportions of Tween, Span, and cholesterol.
Niosomes composed Tween 80 entrapped large amounts of
zidovudine and the addition of dicetyl phosphate enhanced
drug release for a longer time [108]. The drug leakage from
Tween 80 formulations stored at room temperature was
significant compared to niosomes stored at 4∘C for 90 days.
Besides, the results of a pharmacokinetic study in rabbits
also confirmed that Tween 80 formulations with dicetyl
phosphate were cleared from the circulationwithin five hours
[109].
6. Recent Studies
Over the past three decades, niosomes have been successfully
used as a drug carriers to overcome some major biophar-
maceutical problems such as insolubility, side effects, and
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Table 3: Recent studies on niosomes in drug delivery.
Type of the drug Name of the drug Composition Experimental model Year References
Angiotensin receptor
blockers
Candesartan
cilexetil
Span 60, cholesterol,
dicetyl phosphate,
maltodextrin
In vitro dissolution test for
proniosomal tablets, in vivo evaluation
of proniosomal tablets,
pharmacokinetic analysis
2016 [36]
Anti-inflammatory
Naproxen Tween 80, Tween 20,cholesterol
In vitro drug release study,
preformulation study 2016 [37]
Dexamethasone Span 60, cholesterol Characterization of niosomes, in vitrorelease studies, stability test 2015 [38]
Antibacterial
Moxifloxacin Tween 60, cholesterol In vitro release studies, antimicrobialactivity 2016 [39]
Cefixime C-Glycoside derivativesurfactant, cholesterol
In vitro release study, biocompatibility
and bioavailability studies using
experimental animals
2016 [21]
Anticancer
Doxorubicin
Span 60, cholesterol,
dicetyl phosphate,
N-lauryl glucosamine
Optimization studies for formulation,
skin irritancy, histopathological
investigation of rat skin
2016 [35]
Paclitaxel Span 40, cholesterol,dicetyl phosphate
Formulation studies, Pharmacokinetic
and tissue distribution studies 2015 [6]
Antiviral Nevirapine Tyloxapol, cholesterol
Diffusion kinetics of drug,
microviscosity studies, in vitro release
study
2015 [8]
H
2
receptor antagonist Famotidine Span 60, cholesterol Kinetic analysis of drug-releaseprofiles, ex vivo permeability study 2016 [40]
poor chemical stability of drug molecules [110]. Table 3
summarizes themost recent applications of niosomes as drug
delivery systems.
7. Strengths and Limitations of Niosomes in
Drug Delivery
One of the most important strengths of niosomes compared
with liposomes is their chemical stability. Niosomes are more
stable against chemical degradation or oxidation and have
long storage time compared to liposomes [51].The surfactants
which are used for niosomes preparation are biodegradable,
biocompatible, and nonimmunogenic [83]. Handling and
storage conditions of surfactants do not need any specifica-
tions. Moreover composition, size, lamellarity, stability, and
surface charge of niosomes can be controlled by the type of
preparation method, surfactant, cholesterol content, surface
charge additives, and suspension concentration [66].
On the other hand niosomes show physical stability
problems. During storage of dispersion niosomes are at risk
of aggregation, fusion, drug leakage, or hydrolysis of encap-
sulated drugs. Furthermore the sterilization of niosomes
needsmuch effort. Heat sterilization andmembrane filtration
are unsuitable for niosomes. Thus, these areas need further
research to produce commercially niosomal preparations.
8. Conclusion
Niosomes are novel nano drug carriers to design effective
drug delivery systems. They offer a great opportunity for
loading hydrophilic, lipophilic drugs, or both drugs together.
Numbers of studies have been performed with different
types of niosomes in delivery of the anticancer agents, anti-
inflammatory agents, anti-infective agents, and so forth.
The relevant studies demonstrated that niosomes improve
the stability of the entrapped drug, reduce the dose, and
enable targeted delivery to a specific type of tissue. The
structural properties and characteristics of the niosomes
can be enhanced by using novel preparations, loading, and
modificationmethods for particular routes of administration.
Thus, niosomes present itself as promising tools in commer-
cially available therapeutics.
Competing Interests
The authors declare that there are no competing interests
regarding the publication of this paper.
Acknowledgments
Konrad Adenauer Foundation is acknowledged for the finan-
cial support to Didem Ag Seleci. The publication of this
paper was funded by the Open Access Fund of the Leibniz
Universita¨t Hannover.
References
[1] M. Seleci, D. Ag Seleci, R. Joncyzk, F. Stahl, C. Blume, and T.
Scheper, “Smart multifunctional nanoparticles in nanomedi-
cine,” BioNanoMaterials, vol. 17, no. 1-2, pp. 33–41, 2016.
[2] N. B. Mahale, P. D. Thakkar, R. G. Mali, D. R. Walunj, and
S. R. Chaudhari, “Niosomes: novel sustained release nonionic
10 Journal of Nanomaterials
stable vesicular systems—an overview,”Advances in Colloid and
Interface Science, vol. 183, pp. 46–54, 2012.
[3] L. Tavano, L. Gentile, C. Oliviero Rossi, and R. Muzzalupo,
“Novel gel-niosomes formulations as multicomponent systems
for transdermal drug delivery,” Colloids and Surfaces B: Bioint-
erfaces, vol. 110, pp. 281–288, 2013.
[4] K. B. Bini, D. Akhilesh, P. Prabhakara, and K. Jv, “Development
and characterization of non-ionic surfactant vesicles (nio-
somes) for oral delivery of lornoxicam,” International Journal of
Drug Development and Research, vol. 4, no. 3, pp. 147–154, 2012.
[5] Q. Li, Z. Li, W. Zeng et al., “Proniosome-derived niosomes for
tacrolimus topical ocular delivery: in vitro cornea permeation,
ocular irritation, and in vivo anti-allograft rejection,” European
Journal of Pharmaceutical Sciences, vol. 62, pp. 115–123, 2014.
[6] Z. S. Bayindir, A. Bes¸ikci, and N. Yu¨ksel, “Paclitaxel-loaded
niosomes for intravenous administration: pharmacokinetics
and tissue distribution in rats,” Turkish Journal of Medical
Sciences, vol. 45, no. 6, pp. 1403–1412, 2015.
[7] C. Marianecci, F. Rinaldi, M. Mastriota et al., “Anti-inflamma-
tory activity of novel ammonium glycyrrhizinate/niosomes
delivery system: human and murine models,” Journal of Con-
trolled Release, vol. 164, no. 1, pp. 17–25, 2012.
[8] S. K. Mehta and N. Jindal, “Tyloxapol niosomes as prospective
drug delivery module for antiretroviral drug nevirapine,” AAPS
PharmSciTech, vol. 16, no. 1, pp. 67–75, 2014.
[9] P. Arunothayanun,M.-S. Bernard,D.Q.M.Craig, I. F. Uchegbu,
and A. T. Florence, “The effect of processing variables on the
physical characteristics of non-ionic surfactant vesicles (nio-
somes) formed from a hexadecyl diglycerol ether,” International
Journal of Pharmaceutics, vol. 201, no. 1, pp. 7–14, 2000.
[10] A. Pardakhty, J. Varshosaz, and A. Rouholamini, “In vitro study
of polyoxyethylene alkyl ether niosomes for delivery of insulin,”
International Journal of Pharmaceutics, vol. 328, no. 2, pp. 130–
141, 2007.
[11] M. Manconi, D. Valenti, C. Sinico, F. Lai, G. Loy, and A. M.
Fadda, “Niosomes as carriers for tretinoin: II. Influence of vesic-
ular incorporation on tretinoin photostability,” International
Journal of Pharmaceutics, vol. 260, no. 2, pp. 261–272, 2003.
[12] Z. S. Bayindir and N. Yuksel, “Characterization of niosomes
prepared with various nonionic surfactants for paclitaxel oral
delivery,” Journal of Pharmaceutical Sciences, vol. 99, no. 4, pp.
2049–2060, 2010.
[13] D. Paolino, D. Cosco, R. Muzzalupo, E. Trapasso, N. Picci,
and M. Fresta, “Innovative bola-surfactant niosomes as topical
delivery systems of 5-fluorouracil for the treatment of skin
cancer,” International Journal of Pharmaceutics, vol. 353, no. 1-
2, pp. 233–242, 2008.
[14] D. Paolino, R. Muzzalupo, A. Ricciardi, C. Celia, N. Picci, and
M. Fresta, “In vitro and in vivo evaluation of Bola-surfactant
containing niosomes for transdermal delivery,” Biomedical
Microdevices, vol. 9, no. 4, pp. 421–433, 2007.
[15] T. Yoshioka, B. Sternberg, and A. T. Florence, “Preparation
and properties of vesicles (niosomes) of sorbitan monoesters
(Span 20, 40, 60 and 80) and a sorbitan triester (Span 85),”
International Journal of Pharmaceutics, vol. 105, no. 1, pp. 1–6,
1994.
[16] V. C.Okore, A. A.Attama, K. C.Ofokansi, C.O. Esimone, and E.
B. Onuigbo, “Formulation and evaluation of niosomes,” Indian
Journal of Pharmaceutical Sciences, vol. 73, no. 3, pp. 323–328,
2011.
[17] D. Akhilesh, K. B. Bini, and J. V. Kamath, “Review on span-60
based non-ionic surfactant vesicles (niosomes) as novel drug
delivery,” International Journal of Research in Pharmaceutical
and Biomedical Sciences, vol. 3, pp. 6–12, 2012.
[18] C. P. Jain and S. P. Vyas, “Preparation and characterization of
niosomes containing rifampicin for lung targeting,” Journal of
Microencapsulation, vol. 12, no. 4, pp. 401–407, 1995.
[19] S. Mandal, C. Banerjee, S. Ghosh, J. Kuchlyan, and N. Sarkar,
“Modulation of the photophysical properties of curcumin in
nonionic surfactant (Tween-20) forming micelles and nio-
somes: a comparative study of different microenvironments,”
The Journal of Physical Chemistry B, vol. 117, no. 23, pp. 6957–
6968, 2013.
[20] L. Di Marzio, C. Marianecci, M. Petrone, F. Rinaldi, and
M. Carafa, “Novel pH-sensitive non-ionic surfactant vesicles:
comparison between Tween 21 and Tween 20,” Colloids and
Surfaces B: Biointerfaces, vol. 82, no. 1, pp. 18–24, 2011.
[21] M. Imran,M. R. Shah, F.Ullah et al., “Glycoside-based niosomal
nanocarrier for enhanced in-vivo performance of Cefixime,”
International Journal of Pharmaceutics, vol. 505, no. 1-2, pp. 122–
132, 2016.
[22] M. Manconi, C. Sinico, D. Valenti, F. Lai, and A. M. Fadda,
“Niosomes as carriers for tretinoin: III. A study into the
in vitro cutaneous delivery of vesicle-incorporated tretinoin,”
International Journal of Pharmaceutics, vol. 311, no. 1-2, pp. 11–19,
2006.
[23] P. Bandyopadhyay andM. Johnson, “Fatty alcohols or fatty acids
as niosomal hybrid carrier: effect on vesicle size, encapsulation
efficiency and in vitro dye release,” Colloids and Surfaces B:
Biointerfaces, vol. 58, no. 1, pp. 68–71, 2007.
[24] L. Tavano, R.Muzzalupo, L. Mauro,M. Pellegrino, S. Ando`, and
N. Picci, “Transferrin-conjugated Pluronic niosomes as a new
drug delivery system for anticancer therapy,” Langmuir, vol. 29,
no. 41, pp. 12638–12646, 2013.
[25] R.Muzzalupo, L. Tavano, R. Cassano, S. Trombino, T. Ferrarelli,
and N. Picci, “A new approach for the evaluation of niosomes as
effective transdermal drug delivery systems,” European Journal
of Pharmaceutics and Biopharmaceutics, vol. 79, no. 1, pp. 28–35,
2011.
[26] M. Bragagni, N. Mennini, S. Furlanetto, S. Orlandini, C.
Ghelardini, and P. Mura, “Development and characterization of
functionalized niosomes for brain targeting of dynorphin-B,”
European Journal of Pharmaceutics and Biopharmaceutics, vol.
87, no. 1, pp. 73–79, 2014.
[27] S. P. Vyas, R. P. Singh, S. Jain et al., “Non-ionic surfactant based
vesicles (niosomes) for non-invasive topical genetic immuniza-
tion against hepatitis B,” International Journal of Pharmaceutics,
vol. 296, no. 1-2, pp. 80–86, 2005.
[28] A. Sankhyan and P. Pawar, “Recent trends in niosome as vesic-
ular drug delivery system,” Journal of Applied Pharmaceutical
Science, vol. 2, no. 6, pp. 20–32, 2012.
[29] V. B. Junyaprasert, V. Teeranachaideekul, and T. Supaperm,
“Effect of charged and non-ionic membrane additives on
physicochemical properties and stability of niosomes,” AAPS
PharmSciTech, vol. 9, no. 3, pp. 851–859, 2008.
[30] M. Bragagni, N. Mennini, C. Ghelardini, and P. Mura, “Devel-
opment and characterization of niosomal formulations of dox-
orubicin aimed at brain targeting,” Journal of Pharmacy and
Pharmaceutical Sciences, vol. 15, no. 1, pp. 184–196, 2012.
[31] C. Dufes, F. Gaillard, I. F. Uchegbu, A. G. Scha¨tzlein, J.-C.
Olivier, and J.-M. Muller, “Glucose-targeted niosomes deliver
vasoactive intestinal peptide (VIP) to the brain,” International
Journal of Pharmaceutics, vol. 285, no. 1-2, pp. 77–85, 2004.
Journal of Nanomaterials 11
[32] L. Tavano,M.Vivacqua, V. Carito, R.Muzzalupo,M.C. Caroleo,
and F. Nicoletta, “Doxorubicin loaded magneto-niosomes for
targeted drug delivery,” Colloids and Surfaces B: Biointerfaces,
vol. 102, pp. 803–807, 2013.
[33] M. Hong, S. Zhu, Y. Jiang, G. Tang, and Y. Pei, “Efficient tumor
targeting of hydroxycamptothecin loaded PEGylated niosomes
modified with transferrin,” Journal of Controlled Release, vol.
133, no. 2, pp. 96–102, 2009.
[34] C. Dufes, J.-M. Muller, W. Couet, J.-C. Olivier, I. F. Uchegbu,
and A. G. Scha¨tzlein, “Anticancer drug delivery with transferrin
targeted polymeric chitosan vesicles,” Pharmaceutical Research,
vol. 21, no. 1, pp. 101–107, 2004.
[35] S. Pawar and P. Vavia, “Glucosamine anchored cancer targeted
nano-vesicular drug delivery system of doxorubicin,” Journal of
Drug Targeting, vol. 24, no. 1, pp. 68–79, 2016.
[36] N. Yuksel, Z. S. Bayindir, E. Aksakal, andA. T.Ozcelikay, “In situ
niosome forming maltodextrin proniosomes of candesartan
cilexetil: in vitro and in vivo evaluations,” International Journal
of Biological Macromolecules, vol. 82, pp. 453–463, 2016.
[37] N. Shah, “Characterization, optimization and formulation of
niosome containing naproxen,” Journal of Biomedical and Phar-
maceutical Research, vol. 5, no. 1, pp. 1–6, 2016.
[38] M. A. Mavaddati, F. Moztarzadeh, and F. Baghbani, “Effect
of formulation and processing variables on dexamethasone
entrapment and release of niosomes,” Journal of Cluster Science,
vol. 26, no. 6, pp. 2065–2078, 2015.
[39] S. Sohrabi, A. Haeri, A. Mahboubi, A. Mortazavi, and
S. Dadashzadeh, “Chitosan gel-embedded moxifloxacin nio-
somes: an efficient antimicrobial hybrid system for burn infec-
tion,” International Journal of BiologicalMacromolecules, vol. 85,
pp. 625–633, 2016.
[40] V. J. Mokale, H. I. Patil, A. P. Patil, P. R. Shirude, and J. B. Naik,
“Formulation and optimisation of famotidine proniosomes: an
in vitro and ex vivo study,” Journal of Experimental Nanoscience,
vol. 11, no. 2, pp. 97–110, 2016.
[41] J. Jiao, “Polyoxyethylated nonionic surfactants and their appli-
cations in topical ocular drug delivery,”Advanced Drug Delivery
Reviews, vol. 60, no. 15, pp. 1663–1673, 2008.
[42] I. F. Uchegbu and A. T. Florence, “Non-ionic surfactant vesicles
(niosomes): physical and pharmaceutical chemistry,” Advances
in Colloid and Interface Science, vol. 58, no. 1, pp. 1–55, 1995.
[43] A. Shahiwala and A. Misra, “Studies in topical application of
niosomally entrapped nimesulide,” Journal of Pharmacy and
Pharmaceutical Sciences, vol. 5, no. 3, pp. 220–225, 2002.
[44] V. Sharma, S. Anandhakumar, and M. Sasidharan, “Self-
degrading niosomes for encapsulation of hydrophilic and
hydrophobic drugs: an efficient carrier for cancer multi-drug
delivery,”Materials Science and Engineering: C, vol. 56, pp. 393–
400, 2015.
[45] G. Caracciolo, D. Pozzi, R. Caminiti et al., “Effect of hydration
on the structure of solid-supported Niosomal membranes
investigated by in situ energy dispersive X-ray diffraction,”
Chemical Physics Letters, vol. 462, no. 4-6, pp. 307–312, 2008.
[46] B. Nasseri, “Effect of cholesterol and temperature on the elastic
properties of niosomal membranes,” International Journal of
Pharmaceutics, vol. 300, no. 1-2, pp. 95–101, 2005.
[47] C. Marianecci, L. Di Marzio, F. Rinaldi et al., “Niosomes from
80s to present: the state of the art,” Advances in Colloid and
Interface Science, vol. 205, pp. 187–206, 2014.
[48] G. P. Kumar and P. Rajeshwarrao, “Nonionic surfactant vesic-
ular systems for effective drug delivery-an overview,” Acta
Pharmaceutica Sinica B, vol. 1, no. 4, pp. 208–219, 2011.
[49] S. Biswal, P. N. Murthy, J. Sahu, P. Sahoo, and F. Amir,
“Vesicles of non-ionic surfactants (niosomes) and drug delivery
potential,” Internatinal Journal of Pharmaceutical Sciences and
Nanotechnology, vol. 1, no. 1, pp. 1–8, 2008.
[50] J. N. Israelachvili, Intermolecular and Surface Forces, 1985,
Academic Press, New York, NY, USA, 1985.
[51] I. F. Uchegbu and S. P. Vyas, “Non-ionic surfactant based
vesicles (niosomes) in drug delivery,” International Journal of
Pharmaceutics, vol. 172, no. 1-2, pp. 33–70, 1998.
[52] R. A. Khalil and A.-H. A. Zarari, “Theoretical estimation of
the critical packing parameter of amphiphilic self-assembled
aggregates,” Applied Surface Science, vol. 318, pp. 85–89, 2014.
[53] S. Moghassemi and A. Hadjizadeh, “Nano-niosomes as
nanoscale drug delivery systems: an illustrated review,” Journal
of Controlled Release, vol. 185, no. 1, pp. 22–36, 2014.
[54] T. Liu, R. Guo, W. Hua, and J. Qiu, “Structure behaviors of
hemoglobin in PEG6000/Tween 80/Span 80/H
2
Oniosome sys-
tem,” Colloids and Surfaces A: Physicochemical and Engineering
Aspects, vol. 293, no. 1–3, pp. 255–261, 2007.
[55] S. Agarwal, V. Bakshi, P. Vitta, A. P. Raghuram, S. Pandey,
and N. Udupa, “Effect of cholesterol content and surfactant
HLB on vesicle properties of niosomes,” Indian Journal of
Pharmaceutical Sciences, vol. 66, no. 1, pp. 121–123, 2004.
[56] M. Mokhtar, O. A. Sammour, M. A. Hammad, and N. A.
Megrab, “Effect of some formulation parameters on flurbipro-
fen encapsulation and release rates of niosomes prepared from
proniosomes,” International Journal of Pharmaceutics, vol. 361,
no. 1-2, pp. 104–111, 2008.
[57] S. Bhaskaran and P. K. Lakshmi, “Comparative evaluation of
niosome formulations prepared by different techniques,” Acta
Pharmaceutica Sciencia, vol. 51, no. 1, pp. 27–32, 2009.
[58] A. J. Baillie, A. T. Florence, L. R. Hume, G. T. Muirhead, and
A. Rogerson, “The preparation and properties of niosomes
non-ionic surfactant vesicles,” The Journal of Pharmacy and
Pharmacology, vol. 37, no. 12, pp. 863–868, 1985.
[59] A. Marwa, S. Omaima, E. L. G. Hanaa, and A.-S. Mohammed,
“Preparation and in-vitro evaluation of diclofenac sodium nio-
somal formulations,” International Journal of Pharmaceutical
Sciences and Research, vol. 4, no. 5, pp. 1757–1765, 2013.
[60] A. Rogerson, J. Cummings, N. Willmott, and A. T. Florence,
“The distribution of doxorubicin in mice following administra-
tion in niosomes,” Journal of Pharmacy and Pharmacology, vol.
40, no. 5, pp. 337–342, 1988.
[61] S. Srinivas, Y. A. Kumar, A. Hemanth, andM. Anitha, “Prepara-
tion and evaluation of niosomes containing aceclofenac,”Digest
Journal of Nanomaterials and Biostructures, vol. 5, no. 1, pp. 249–
254, 2010.
[62] S. Moghassemi, E. Parnian, A. Hakamivala et al., “Uptake and
transport of insulin across intestinal membrane model using
trimethyl chitosan coated insulin niosomes,” Materials Science
and Engineering C, vol. 46, pp. 333–340, 2015.
[63] A. Budhiraja and G. Dhingra, “Development and characteriza-
tion of a novel antiacne niosomal gel of rosmarinic acid,” Drug
Delivery, vol. 22, no. 6, pp. 723–730, 2015.
[64] H. Kiwada, H. Niimura, Y. Fujisaki, S. Yamada, and Y. Kato,
“Application of synthetic alkyl glycoside vesicles as drug car-
riers. I. Preparation and physical properties,” Chemical and
Pharmaceutical Bulletin, vol. 33, no. 2, pp. 753–759, 1985.
[65] A. S. Zidan, Z. Rahman, and M. A. Khan, “Product and
process understanding of a novel pediatric anti-HIV tenofovir
niosomes with a high-pressure homogenizer,” European Journal
of Pharmaceutical Sciences, vol. 44, no. 1-2, pp. 93–102, 2011.
12 Journal of Nanomaterials
[66] S. Verma, S. K. Singh, N. Syan, P. Mathur, and V. Valecha,
“Nanoparticle vesicular systems: a versatile tool for drug deliv-
ery,” Journal of Chemical and Pharmaceutical Research, vol. 2,
no. 2, pp. 496–509, 2010.
[67] A. Manosroi, R. Chutoprapat, M. Abe, and J. Manosroi, “Char-
acteristics of niosomes prepared by supercritical carbon dioxide
(scCO
2
) fluid,” International Journal of Pharmaceutics, vol. 352,
no. 1-2, pp. 248–255, 2008.
[68] A.Manosroi,W. Ruksiriwanich,M. Abe, H. Sakai,W.Manosroi,
and J. Manosroi, “Biological activities of the rice bran extract
and physical characteristics of its entrapment in niosomes by
supercritical carbon dioxide fluid,” The Journal of Supercritical
Fluids, vol. 54, no. 2, pp. 137–144, 2010.
[69] V. R. Yasam, S. L. Jakki, J. Natarajan, and G. Kuppusamy, “A
review on novel vesicular drug delivery: proniosomes,” Drug
Delivery, vol. 21, no. 4, pp. 243–249, 2014.
[70] L. D. Mayer, M. B. Bally, and P. R. Cullis, “Uptake of adriamycin
into large unilamellar vesicles in response to a pH gradient,”
Biochimica et Biophysica Acta (BBA)—Biomembranes, vol. 857,
no. 1, pp. 123–126, 1986.
[71] A. K. Verma and J. C. Bindal, “A vital role of niosomes on
controlled and novel drug delivery,” Indian Journal of Novel
Drug Delivery, vol. 3, pp. 238–246, 2011.
[72] M. R. Mozafari, “A new technique for the preparation of non-
toxic liposomes and nanoliposomes: the heating method,” in
Nanoliposomes: FromFundamentals to RecentDevelopments, pp.
91–98, Trafford Publishing, Oxford, UK, 2005.
[73] M. R. Mozafari, C. J. Reed, and C. Rostron, “Cytotoxicity eval-
uation of anionic nanoliposomes and nanolipoplexes prepared
by the heating method without employing volatile solvents and
detergents,” Die Pharmazie, vol. 62, no. 3, pp. 205–209, 2007.
[74] H. Talsma, M. J. Van Steenbergen, J. C. H. Borchert, and D. J.
A. Crommelin, “A novel technique for the one-step preparation
of liposomes and nonionic surfactant vesicles without the
use of organic solvents. Liposome formation in a continuous
gas stream: the ‘bubble’ method,” Journal of Pharmaceutical
Sciences, vol. 83, no. 3, pp. 276–280, 1994.
[75] L. Tavano, R. Aiello, G. Ioele, N. Picci, and R. Muzzalupo, “Nio-
somes from glucuronic acid-based surfactant as new carriers
for cancer therapy: preparation, characterization and biological
properties,” Colloids and Surfaces B: Biointerfaces, vol. 118, pp.
7–13, 2014.
[76] A. Priprem, K. Janpim, S. Nualkaew, and P. Mahakunakorn,
“Topical niosome gel of Zingiber cassumunar Roxb. extract
for anti-inflammatory activity enhanced skin permeation and
stability of compoundD,”AAPS PharmSciTech, vol. 17, no. 3, pp.
631–639, 2016.
[77] W. Hua and T. Liu, “Preparation and properties of highly stable
innocuous niosome in Span 80/PEG 400/H
2
O system,”Colloids
and Surfaces A: Physicochemical and Engineering Aspects, vol.
302, no. 1, pp. 377–382, 2007.
[78] A. Manosroi, P. Wongtrakul, J. Manosroi et al., “Characteri-
zation of vesicles prepared with various non-ionic surfactants
mixed with cholesterol,” Colloids and Surfaces B: Biointerfaces,
vol. 30, no. 1-2, pp. 129–138, 2003.
[79] D. Pozzi, R. Caminiti, C. Marianecci et al., “Effect of cholesterol
on the formation and hydration behavior of solid-supported
niosomal membranes,” Langmuir, vol. 26, no. 4, pp. 2268–2273,
2010.
[80] D. Pando, G. Gutie´rrez, J. Coca, and C. Pazos, “Preparation and
characterization of niosomes containing resveratrol,” Journal of
Food Engineering, vol. 117, no. 2, pp. 227–234, 2013.
[81] M. Tabbakhian, S. Daneshamouz, N. Tavakoli, and M. R.
Jaafari, “Influence of liposomes and niosomes on the in vitro
permeation and skin retention of finasteride,” Iranian Journal of
Pharmaceutical Sciences, vol. 1, no. 3, pp. 119–130, 2005.
[82] S. K. Mehta and N. Jindal, “Formulation of Tyloxapol nio-
somes for encapsulation, stabilization and dissolution of anti-
tubercular drugs,”Colloids and Surfaces B: Biointerfaces, vol. 101,
pp. 434–441, 2013.
[83] A. Y. Waddad, S. Abbad, F. Yu et al., “Formulation, charac-
terization and pharmacokinetics of Morin hydrate niosomes
prepared from various non-ionic surfactants,” International
Journal of Pharmaceutics, vol. 456, no. 2, pp. 446–458, 2013.
[84] Y. Hao, F. Zhao, N. Li, Y. Yang, and K. Li, “Studies on a high
encapsulation of colchicine by a niosome system,” International
Journal of Pharmaceutics, vol. 244, no. 1-2, pp. 73–80, 2002.
[85] A. Dwivedi, A. Mazumder, L. du Plessis, J. L. du Preez, R.
K. Haynes, and J. du Plessis, “In vitro anti-cancer effects of
artemisone nano-vesicular formulations on melanoma cells,”
Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 11,
no. 8, pp. 2041–2050, 2015.
[86] R. P. Gude, M. G. Jadhav, S. G. A. Rao, and A. G. Jagtap,
“Effects of niosomal cisplatin and combination of the samewith
theophylline and with activatedmacrophages inmurine B16F10
melanoma model,” Cancer Biotherapy and Radiopharmaceuti-
cals, vol. 17, no. 2, pp. 183–192, 2002.
[87] D. Cosco, D. Paolino, R. Muzzalupo et al., “Novel PEG-coated
niosomes based on bola-surfactant as drug carriers for 5-
fluorouracil,” Biomedical Microdevices, vol. 11, no. 5, pp. 1115–
1125, 2009.
[88] W. Han, S. Wang, R. Liang et al., “Non-ionic surfactant vesicles
simultaneously enhance antitumor activity and reduce the
toxicity of cantharidin,” International Journal of Nanomedicine,
vol. 8, pp. 2187–2196, 2013.
[89] D. S. Shaker, M. A. Shaker, and M. S. Hanafy, “Cellular uptake,
cytotoxicity and in-vivo evaluation of Tamoxifen citrate loaded
niosomes,” International Journal of Pharmaceutics, vol. 493, no.
1-2, pp. 285–294, 2015.
[90] I. F. Uchegbu, J. A. Double, L. R. Kelland, J. A. Turton, and
A. T. Florence, “The activity of doxorubicin niosomes against
an ovarian cancer cell line and three in vivo mouse tumour
models,” Journal of Drug Targeting, vol. 3, no. 5, pp. 399–409,
1996.
[91] D. J. Kerr, A. Rogerson, G. J. Morrison, A. T. Florence, and
S. B. Kaye, “Antitumour activity and pharmacokinetics of
niosome encapsulated adriamycin in monolayer, spheroid and
xenograft,” British Journal of Cancer, vol. 58, no. 4, pp. 432–436,
1988.
[92] S. Y. Gaikwad, A. G. Jagtap, A. D. Ingle, S. G. A. Ra, and R. P.
Gude, “Antimetastatic efficacy of niosomal pentoxifylline and
its combination with activated macrophages in murine B16F10
melanoma model,” Cancer Biotherapy & Radiopharmaceuticals,
vol. 15, no. 6, pp. 605–615, 2000.
[93] M. Kong, H. Park, C. Feng, L. Hou, X. Cheng, and X. Chen,
“Construction of hyaluronic acid noisome as functional trans-
dermal nanocarrier for tumor therapy,” Carbohydrate Polymers,
vol. 94, no. 1, pp. 634–641, 2013.
[94] A. Narang and R. Mahato, Targeted Delivery of Small and
Macromolecular Drugs, CRC Press, 2010.
[95] D. Ag, R. Bongartz, L. E. Dogan et al., “Biofunctional quantum
dots as fluorescence probe for cell-specific targeting,” Colloids
and Surfaces B: Biointerfaces, vol. 114, pp. 96–103, 2014.
Journal of Nanomaterials 13
[96] M. Seleci, D. A. Seleci, M. Ciftci et al., “Nanostructured
amphiphilic star-hyperbranched block copolymers for drug
delivery,” Langmuir, vol. 31, no. 15, pp. 4542–4551, 2015.
[97] S. Gadde, “Multi-drug delivery nanocarriers for combination
therapy,”MedChemComm, vol. 6, no. 11, pp. 1916–1929, 2015.
[98] B. Al-Lazikani, U. Banerji, and P. Workman, “Combinatorial
drug therapy for cancer in the post-genomic era,” Nature
Biotechnology, vol. 30, no. 7, pp. 679–692, 2012.
[99] G. Pasut, F. Greco, A. Mero et al., “Polymer-drug conjugates for
combination anticancer therapy: investigating the mechanism
of action,” Journal of Medicinal Chemistry, vol. 52, no. 20, pp.
6499–6502, 2009.
[100] Y. D. Livney and Y. G. Assaraf, “Rationally designed nanove-
hicles to overcome cancer chemoresistance,” Advanced Drug
Delivery Reviews, vol. 65, no. 13-14, pp. 1716–1730, 2013.
[101] C. Sarisozen, I. Vural, T. Levchenko, A. A. Hincal, and V. P.
Torchilin, “PEG-PE-based micelles co-loaded with paclitaxel
and cyclosporine A or loaded with paclitaxel and targeted by
anticancer antibody overcome drug resistance in cancer cells,”
Drug Delivery, vol. 19, no. 4, pp. 169–176, 2012.
[102] M. Thakkar and S. Brijesh, “Opportunities and challenges for
niosomes as drug delivery systems,” Current Drug Delivery, vol.
13, pp. 1–15, 2016.
[103] L. Tavano, R. Muzzalupo, N. Picci, and B. De Cindio, “Co-
encapsulation of antioxidants into niosomal carriers: gastroin-
testinal release studies for nutraceutical applications,” Colloids
and Surfaces B: Biointerfaces, vol. 114, pp. 82–88, 2014.
[104] C. Marianecci, F. Rinaldi, L. D. Marzio, A. Ciogli, S. Esposito,
and M. Carafa, “Polysorbate 20 vesicles as multi-drug carriers:
in vitro preliminary evaluations,” Letters in Drug Design and
Discovery, vol. 10, no. 3, pp. 212–218, 2013.
[105] K. Begum, A. F. Khan, H. K. Hana, J. Sheak, and R. U.
Jalil, “Rifampicin niosome: preparations, characterizations and
antibacterial activity against staphylococcus aureus and staphy-
lococcus epidermidis isolated from acne,” Dhaka University
Journal of Pharmaceutical Sciences, vol. 14, no. 1, pp. 117–123,
2015.
[106] V. Akbari, D. Abedi, A. Pardakhty, and H. Sadeghi-Aliabadi,
“Release studies on ciprofloxacin loaded non-ionic surfactant
vesicles,” Avicenna Journal of Medical Biotechnology, vol. 7, no.
2, pp. 69–75, 2015.
[107] G. Abdelbary and N. El-Gendy, “Niosome-encapsulated gen-
tamicin for ophthalmic controlled delivery,” AAPS Pharm-
SciTech, vol. 9, no. 3, pp. 740–747, 2008.
[108] K. Ruckmani and V. Sankar, “Formulation and optimization of
zidovudine niosomes,” AAPS PharmSciTech, vol. 11, no. 3, pp.
1119–1127, 2010.
[109] K. Ruckmani, V. Sankar, and M. Sivakumar, “Tissue distri-
bution, pharmacokinetics and stability studies of zidovudine
delivered by niosomes and proniosomes,” Journal of Biomedical
Nanotechnology, vol. 6, no. 1, pp. 43–51, 2010.
[110] H. Abdelkader, A. W. G. Alani, and R. G. Alany, “Recent
advances in non-ionic surfactant vesicles (niosomes): self-
assembly, fabrication, characterization, drug delivery applica-
tions and limitations,” Drug Delivery, vol. 21, no. 2, pp. 87–100,
2014.
Submit your manuscripts at
http://www.hindawi.com
Scientifica
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Corrosion
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Polymer Science
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Ceramics
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Composites
Journal of
Nanoparticles
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
International Journal of
Biomaterials
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Nanoscience
Journal of
Textiles
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Journal of
Nanotechnology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Crystallography
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Coatings
Journal of
Advances in 
Materials Science and Engineering
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Smart Materials 
Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Metallurgy
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Materials
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
N
an
om
at
er
ia
ls
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal ofNanomaterials
